• PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation. 

  Murray, J; Cruickshank, C; Bird, T; Bell, P; Braun, J; et al. (ELSEVIER IRELAND LTD, 2022-11-01)

  PEARLS is a multi-stage randomised controlled trial for prostate cancer patients with pelvic and/or para-aortic PSMA-avid lymph node disease at presentation. The aim of the trial is to determine whether extending the ...
• Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. 

  Bachelot, T; Cottu, P; Chabaud, S; Dalenc, F; Allouache, D; et al. (American Society of Clinical Oncology (ASCO), 2022-11-10)

  PURPOSE: Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor-resistant metastatic ...
• Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. 

  Goodwin, PJ; Chen, BE; Gelmon, KA; Whelan, TJ; Ennis, M; et al. (AMER MEDICAL ASSOC, 2022-05-24)

  Importance: Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. Objective: To determine ...
• Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. 

  Ma, TM; Sun, Y; Malone, S; Roach, M; Dearnaley, D; et al. (American Society of Clinical Oncology (ASCO), 2022-10-21)

  PURPOSE: The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men ...
• Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT. 

  Heer, R; Lewis, R; Duncan, A; Penegar, S; Vadiveloo, T; et al. (NIHR JOURNALS LIBRARY, 2022-10-01)

  BACKGROUND: Around 7500 people are diagnosed with non-muscle-invasive bladder cancer in the UK annually. Recurrence following transurethral resection of bladder tumour is common, and the intensive monitoring schedule ...

View more